Cancer ResearchClinical TrialPaywall

Liver Chemoembolization Plus Apatinib and PD-1 Blockade Tested in Advanced Bile Duct Cancer

A small phase 2 trial tests drug-eluting bead chemoembolization with apatinib and a PD-1 antibody in bile duct cancer that progressed after chemotherapy.

Wednesday, November 18, 2026 2 views
Published in cancer immunotherapy checkpoint
interventional radiologist performing transarterial chemoembolization in an angiography suite with fluoroscopy monitors

Summary

Intrahepatic cholangiocarcinoma is a cancer of the bile ducts inside the liver. Most patients are diagnosed late, and after the standard first-line chemotherapy (gemcitabine plus cisplatin) stops working, there is no agreed second-line treatment. This phase 2 trial, run at Sichuan Cancer Hospital and Research Institute, combines three approaches: drug-eluting bead transarterial chemoembolization (DEB-TACE), which delivers chemotherapy directly to the tumor's blood supply while blocking it; apatinib, a drug that targets tumor blood vessel growth; and a PD-1 antibody, which releases the immune system's brake on cancer cells. The study enrolled 20 adults aged 18 to 80 whose disease progressed after chemotherapy. The record we have lists the design and status as completed, but the abstract reports no results, so we cannot say whether the combination worked or how safe it was.

Detailed Summary

Why this matters: Intrahepatic cholangiocarcinoma makes up roughly 15% to 20% of primary liver cancers, and its incidence is rising. Surgical resection is the main treatment, but about 60% to 70% of patients are diagnosed at an advanced stage. Gemcitabine plus cisplatin is the first-line treatment recommended in international and domestic guidelines. Once the disease progresses after that, there is no established second-line standard.

What was studied: This phase 2 trial, sponsored by Sichuan Cancer Hospital and Research Institute, tests a three-part strategy. DEB-TACE delivers chemotherapy-loaded beads into the artery feeding the tumor and blocks that blood supply. Apatinib is an oral drug aimed at tumor blood vessel growth. A PD-1 antibody, described in the abstract as carrelizumab (likely camrelizumab), blocks an immune checkpoint so T cells can attack the tumor. The mechanistic idea is that combining local tumor destruction, blood vessel suppression and immune activation may work better than any one alone.

Participants: The trial lists enrollment of 20 adults aged 18 to 80 with histologically or cytologically confirmed intrahepatic cholangiocarcinoma that was locally advanced or had multiple liver metastases, including progression after gemcitabine-based chemotherapy. Its stated aim is to assess safety and efficacy.

Key results: None are reported. The abstract is a registry description. The study is listed as completed, with a start date of July 2024 and a completion date of April 2026, but no response rates, survival data or adverse events are given. The abstract notes that the clinical benefits of immune therapies are emerging in hepatocellular carcinoma. It also says early clinical data show immune checkpoint inhibition is safe, but it does not specify which data.

Implications and caveats: Until results are published, this is a trial worth watching, not a treatment option. The abstract does not state whether there is a control arm. Only one combined intervention is listed, and any eventual findings from 20 patients would be hypothesis-generating rather than definitive. This summary is based on the registry abstract only, so design details, endpoints and outcomes could not be verified.

Key Findings

  • No efficacy or safety results are reported in the available abstract; it describes the trial design only.
  • Phase 2 single-intervention trial enrolled 20 adults with intrahepatic cholangiocarcinoma that progressed after gemcitabine-based chemotherapy.
  • The regimen combines DEB-TACE (local), apatinib (anti-angiogenic) and a PD-1 antibody (immune checkpoint blockade).
  • No standard second-line therapy exists after first-line gemcitabine plus cisplatin, which is the gap this trial addresses.
  • Registry lists the study as completed, but outcome data are not yet available in this record.

Methodology

Phase 2 interventional trial with 20 listed participants aged 18 to 80 and histologically or cytologically confirmed intrahepatic cholangiocarcinoma. No registry identifier is given in the source. The abstract does not state whether there is a control arm, the primary endpoints, or dosing, though it frames the aim as assessing safety and efficacy. This summary is based on the abstract only.

Study Limitations

This summary is based on the abstract only, which contains no results, so efficacy and safety cannot be assessed. The sample is small at 20 patients. The abstract does not describe a control arm, and only a single combined intervention is listed, which limits any conclusions. The abstract names the PD-1 agent imprecisely (carrelizumab). It also cites early safety data for checkpoint inhibition without specifying their source or population.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: